Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | opioid receptor, kappa 1 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 2, subfamily D, polypeptide 6 | Starlite/ChEMBL | References |
Homo sapiens | opioid receptor, mu 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | cytochrome P450 | cytochrome P450, family 2, subfamily D, polypeptide 6 | 497 aa | 425 aa | 32.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | NNMT/PNMT/TEMT family protein | 0.2249 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2249 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2249 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 95 % | In vivo antinociception in mice at 300 ug given intrapaw by late phase formalin-induced flinching assay | ChEMBL. | 16203140 |
Activity (functional) | = 95 % | In vivo antinociception in mice at 300 ug given intrapaw by late phase formalin-induced flinching assay | ChEMBL. | 16203140 |
ED50 (functional) | = 0.53 mg kg-1 | In vivo inhibition of acetic acid-induced writhing in mice after sc administration | ChEMBL. | 16203140 |
ED50 (functional) | = 0.53 mg kg-1 | In vivo inhibition of acetic acid-induced writhing in mice after sc administration | ChEMBL. | 16203140 |
ED50 (functional) | = 1 mg kg-1 | In vivo inhibition of acetic acid-induced writhing in mice after oral administration | ChEMBL. | 16203140 |
ED50 (functional) | = 1 mg kg-1 | In vivo inhibition of acetic acid-induced writhing in mice after oral administration | ChEMBL. | 16203140 |
IC50 (ADMET) | = 4200 nM | Inhibitory activity against CYP2D6 | ChEMBL. | 16203140 |
IC50 (ADMET) | = 4200 nM | Inhibitory activity against CYP2D6 | ChEMBL. | 16203140 |
Ki (functional) | = 2.6 nM | Agonistic activity at kappa opioid receptor | ChEMBL. | 16203140 |
Ki (functional) | = 2.6 nM | Agonistic activity at kappa opioid receptor | ChEMBL. | 16203140 |
Ki (functional) | > 5 uM | Agonistic activity at mu opioid receptor | ChEMBL. | 16203140 |
Ki (functional) | > 5 uM | Agonistic activity at mu opioid receptor | ChEMBL. | 16203140 |
Ratio Ki (binding) | = 615 | Selectivity for delta opioid receptor over kappa opioid receptor | ChEMBL. | 16203140 |
Ratio Ki (binding) | > 1923 | Selectivity for mu opioid receptor over kappa opioid receptor | ChEMBL. | 16203140 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.